1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) is sponsored by National Institute on Aging (NIA). This program supports exploratory and developmental research to address gaps in Alzheimer's disease and related dementias (AD/ADRD) research. Proposals focusing on communication and cognition in older adults with cognitive impairment would be appropriate.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-AG-25-023: Notice of Early Expiration of PAR-25-331, "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" Notice of Early Expiration of PAR-25-331, "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" December 30, 2024 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional).
See NOFO PAR-25-331 . This Notice informs applicants that, effective immediately, PAR-25-331 , Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) is expired. No further applications will be accepted for PAR-25-331 .
However, applicants can submit an unsolicited grant application to any of the NIH Parent NOFOs . For more information regarding PAR-25-331 , applicants may refer to NIAs web page . Please direct all inquiries to: NIA Scientific Program Contact Weekly TOC for this Announcement NIH...
Turning Discovery Into Health ®
According to the current listing, eligibility includes: Higher education institutions, Nonprofits, For-profit organizations, Small businesses, Governments, and others. Individuals are encouraged to apply as part of an institutional application. Confirm the full requirements in the official notice before applying.
Applications for Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) are due November 6, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) is funded by National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article